retatrutide phase 2 nejm 2023 percent weight loss 48 weeks Retatrutide (not yet approved in US but people using anyway) promises even potentially greater weight loss amongst the GLP1 drugs. https://www.nejm .org/doi/full/10.1056/NEJMoa2301972 Retatrutide Availability & Timeline |

Regulating Satiety Pathways: In the hypothalamus, GLP-1 RAs stimulate neurons that promote satiety (POMC/CART neurons) and inhibit neurons that drive hunger (NPY/AgRP neurons), reducing food intake and enhancing fullness (Zheng et al., 2024)

Musculoskeletal MRI (Third ed.)

For subcutaneous injections, a standard insulin syringe is typically used

OKane, D., V

Gastric mucosal protection: from the periphery to the central nervous system

Future prospective studies may consider using a validated objective scoring method to standardize the definition of retained gastric contents (e.g., POLPREP) ( Patient demographic data was also limited to what patients chose to disclose